New investigational combinations for higher-risk MDS

Kristin L. Koenig, Uma Borate

Research output: Contribution to journalArticlepeer-review

Abstract

Myelodysplastic syndromes (MDS) are typically a hematologic malignancy of older adults characterized by dysplastic hematopoiesis, cytopenia(s), and risk of acute myeloid leukemia transformation. The treatment approach to MDS depends largely on risk stratification of an individual's disease, most commonly using the Revised International Prognostic Scoring System, which takes into account peripheral blood cytopenias and bone marrow blast percentage and cytogenetics. The current standard of care for patients with higher-risk MDS (HR-MDS) includes hypomethylating agents (HMAs), decitabine and azacitidine, and allogenic stem cell transplant for patients able to undergo this therapy. However, leukemic transformation remains a significant challenge, and outcomes with these current therapies are still dismal. There are several novel therapies in development aiming to improve upon the outcomes of single-agent HMA therapy using combination strategies with HMAs. Here we discuss the current standard of care for HR-MDS treatment and explore some of the most promising combination therapies coming out of the pipeline for HR-MDS.

Original languageEnglish (US)
Pages (from-to)368-374
Number of pages7
JournalHematology. American Society of Hematology. Education Program
Volume2022
Issue number1
DOIs
StatePublished - Dec 9 2022
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'New investigational combinations for higher-risk MDS'. Together they form a unique fingerprint.

Cite this